Immunomodulation and endothelial barrier protection mediate the association between oral imatinib and mortality in hospitalised COVID-19 patients.
Justin de BrabanderErik DuijvelaarJob R SchippersPatrick J SmeeleHessel Peters SengersJan Willem DuitmanJurjan AmanHarm J BogaardTom van der PollLieuwe D J Bosnull nullPublished in: The European respiratory journal (2022)
The effect of imatinib on mortality in hospitalised COVID-19 patients is mediated through modulation of innate immune responses and reversal of endothelial dysfunction, and possibly moderated by biological subphenotypes.